CERS
Companies
NASDAQ
Cerus Corporation
Health Care
$1.34
-$0.17 (-11.04%)
Price Chart
Overview
About CERS
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Market Cap
$329.1M
Volume
1.4M
Avg. Volume
1.5M
P/E Ratio
-19.142857
Dividend Yield
0.00%
Employees
343.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.34
High Correlation
Volatility
High (0.69)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CERS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$329.1M
Volume1.4M
P/E Ratio-19.14
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 2, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025